We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Available until 7/1/2023

Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.

Already Have An Account? Log in Now

story of the week
Published in Eye Care

Journal Scan / Research · May 23, 2023

Risks Associated With Topical Carbonic Anhydrase Inhibitor Use in Patients With Glaucoma and Chronic Kidney Disease

American Journal of Ophthalmology




This abstract is available on the publisher's site.

Access this abstract now   Full Text Available for ClinicalKey Subscribers

Additional Info

American Journal of Ophthalmology
Risks of Topical Carbonic Anhydrase Inhibitors in Glaucoma Patients with Chronic Kidney Disease: A Nationwide Population-Based Study
Am J Ophthalmol 2023 May 04;[EPub Ahead of Print], YC Wang, XC Ling, WH Tsai, JS Liu, KL Kuo

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading